Latest news

New economic modelling suggests improvements in chronic kidney disease care could deliver £69.4 million of benefits in the first year and £334.9 million over five years if achieved across England.

 A model of chronic kidney disease (CKD) care developed and evaluated in Leicester, Leicestershire and Rutland is being rolled out across England through the Health Innovation Network.

LUCID – Connecting Kidney Care brings specialist kidney expertise closer to patients by linking primary and secondary care. Its approach combines identifying people at risk, clinician education and patient self-management support, multidisciplinary case review, medicines optimisation and ongoing coordinated care of patients living with CKD.

The national three-year programme is being taken forward by all 15 health innovation networks across England, with Health Innovation East Midlands leading the programme. It aims to support earlier identification and intervention, improve patient outcomes and enable more people to receive appropriate care closer to home, while ensuring those at higher risk are referred for specialist care when needed.

New economic analysis by Frontier Economics illustrates the potential national opportunity if improvements associated with the LUCID model were achieved across England.

Under an illustrative scenario in which LUCID-level improvements were achieved at full national coverage, the modelling estimates:

  • £69.4 million of benefits in year one
  • £334.9 million of benefits over five years
  • a five-year return on investment of 3.25, meaning each £1 invested is modelled to return the original £1 plus £3.25 in net societal benefits.

The modelled benefits include improvements in patient health and more efficient use of NHS resources, through optimised medicines, better-informed treatment decisions in primary care and more timely access to specialist advice.

CKD affects around 7.2 million people in the UK and is associated with increased risks of cardiovascular disease, kidney failure, hospitalisation and premature mortality. Care can be fragmented across GP practices, nephrology teams and hospital outpatient services. LUCID is designed to bridge those boundaries, helping primary care teams identify and manage patients earlier and make better-informed decisions about who needs specialist referral.

The national programme builds on experience in Leicester, Leicestershire and Rutland, where an independent evaluation found patient and system benefits from improved CKD management in primary care and positive changes to the use of secondary care. The approach is now being adapted for implementation by local health systems across England. 

The national roll-out is launching today at Willows Health, Leicester, an early adopter of the LUCID programme.

Willows Health has been a LUCID pilot site since 2022 and helped shape the programme’s virtual Multidisciplinary Team (MDT) model. 

The practice runs monthly nephrology MDTs, reviewing up to 40 patients with complex Chronic Kidney Disease (CKD) at a time. This enables patients with the greatest clinical complexity and those at highest risk of disease progression to benefit from earlier access to specialist advice, supporting timely, informed decisions about their care.

The original LUCID programme was developed through a Joint Working Agreement between the John Walls Renal Unit at University Hospitals of Leicester NHS Trust and AstraZeneca UK. That Joint Working project has concluded, and AstraZeneca UK has now signed a Memorandum of Understanding with Health Innovation East Midlands to share expertise and insights on the future implementation and scaling of LUCID.  

Professor Ben Bridgewater, Executive Chair of the Health Innovation Network, said: “The NHS does not have an invention challenge; it has an implementation challenge. LUCID is exactly the kind of proven innovation we need to take from successful local delivery to national scale.

“By bringing specialist kidney expertise closer to patients, it has the potential to improve outcomes while making better use of NHS resources. This new modelling shows the scale of the opportunity, up to £69.4 million of benefits in the first year and a five year return on investment of 3.25. The impact of innovations like this make it clear - when we align the system around high-impact innovations and support their adoption properly, local change can deliver national impact.”

Nicole McGlennon, Chief Executive, Health Innovation East Midlands said: “We’re excited to be working with Health Innovation Network teams across the country to share the learning and resources developed in Leicester, Leicestershire and Rutland. The potential benefits of rolling the programme out across the NHS are huge. The programme aims to create a sustainable way of delivering care that benefits the NHS and as many patients as possible during the next three years, and beyond.”

Dr Rupert Major, Clinical Associate Professor at University of Leicester, Consultant Nephrologist at University Hospitals of Leicester NHS Trust and Clinical Lead for LUCID in Leicester, Leicestershire and Rutland Integrated Care Board, said:

“Kidney disease is common, serious and often isn't picked up until quite late. The good news is that we now have better tests, better treatments and better ways of joining up care. The challenge is making sure people benefit from them.

“LUCID was developed in Leicester, Leicestershire and Rutland to help patients get the right treatment earlier and closer to home, with GP teams and kidney specialists - including doctors, nurses and pharmacists - working together rather than in separate parts of the system.

“This is exactly the kind of change the NHS is trying to make: preventing illness rather than reacting to it, supporting more care in the community, and using data and technology to identify people before they become seriously unwell. Because kidney disease and cardiovascular disease are so closely linked, improving kidney care also means preventing heart attacks, strokes and avoidable hospital admissions. Ultimately, it's about helping people stay healthier for longer and reducing the need for more intensive treatment, like dialysis, later on.

“As someone whose career and personal development has been supported by both Kidney Research UK and the National Institute for Health and Care Research (NIHR), I'm incredibly proud to see our local work impacting on care nationally and beyond".

Dr Melanie Morris, GP and Clinical Fellow in Integrated Kidney Care (LUCID) said: 

“Primary care plays a vital role in managing the vast majority of people living with chronic kidney disease (CKD). This starts with early diagnosis, clear communication and accessible resources to help patients understand and manage their condition, alongside support to optimise treatment. 

“For patients with more complex needs or at higher risk of disease progression, timely access to specialist advice is essential. LUCID helps make all of this possible by bringing primary and specialist care closer together, enabling us to make informed decisions and provide the right care for our patients at the right time.

“By sharing specialist expertise and learning, LUCID also helps strengthen CKD management across primary care, benefiting not only those patients discussed in multidisciplinary team meetings, but the wider population of people living with the condition.”

Dr Alexander Gueret-Wardle, Medical Director at AstraZeneca UK, said: "It's incredibly rewarding to see LUCID, a programme designed in partnership, now being scaled nationally. It shows how collaboration can turn shared ambition and innovation into better care for people with chronic kidney disease. We're proud of AstraZeneca's role and delighted to continue supporting national implementation."